Skip to main content
Clinical Trials/NCT07403175
NCT07403175
Completed
Not Applicable

Synergistic Impact of Postural Correction Interventions and Sustained Natural Apophyseal Glides on Severity, Disability and Quality of Life in Patients With Migraine

Riphah International University1 site in 1 country44 target enrollmentStarted: January 10, 2025Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
44
Locations
1
Primary Endpoint
Numeric Pain Rating Scale (NPRS)

Overview

Brief Summary

This study was conducted to evaluate the synergistic impact of postural correction interventions and sustained natural apophyseal glides on severity, quality of life and disability in patients with migraine.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
22 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • A diagnosis of episodic migraine made by the primary investigator according to ICHD-
  • Symptoms must include at least two of the following: Unilateral pain, Pulsating/throbbing pain, Nausea, Vomiting, Photophobia/phonophobia.
  • Participants should be full time employees or Desktop users.
  • Participants have a history of at least migraine \>4 days per month.
  • Participants having history of migraine lasting from 4-72 hours
  • Age group between 22 and 45 years.
  • Both gender male and female.
  • Participants who agree to cut-off any pharmacological treatment during study.
  • Participants should have an average score between 3-6 on pain intensity scale.

Exclusion Criteria

  • Participants having active migraine and other headache types e.g. Cluster headache.
  • Previous neck/head trauma from \>2 years.
  • Any neck/head surgery \>2 years
  • Spinal infections/diseases e.g. Tumor, TB spine
  • Any history of neurological disorders e.g. stroke, abcess, haemorrhage, haematoma
  • Severe Osteoporosis
  • Pregnancy
  • Upper motor neuron disease, cervical stenosis, and metabolic diseases in bone and joint.
  • Ongoing radiotherapy, chemotherapy, steroid therapy, or anticoagulants.
  • Psychiatric diseases such as phobia/obsession and depression.

Arms & Interventions

Sustained Natural Apophyseal Glides & Postural Correction Exercises

Experimental

Intervention: Sustained Natural Apophyseal Glides (Other)

Sustained Natural Apophyseal Glides & Postural Correction Exercises

Experimental

Intervention: Postural Correction Exercises (Other)

Sustained Natural Apophyseal Glides & Postural Correction Exercises

Experimental

Intervention: Conventional Physical Therapy (Other)

Sustained Natural Apophyseal Glides

Active Comparator

Intervention: Sustained Natural Apophyseal Glides (Other)

Sustained Natural Apophyseal Glides

Active Comparator

Intervention: Conventional Physical Therapy (Other)

Outcomes

Primary Outcomes

Numeric Pain Rating Scale (NPRS)

Time Frame: From enrollment to the end of treatment at 4 weeks.

The NRS is used to gauge the patient's degree of pain. On a 0-10 scale, where 0 represents no pain, 1-3 represents mild pain, 4-6 represents moderate pain, and 7-10 represents severe pain, this tool is frequently used to gauge the intensity of pain. Patients rate how much pain they are currently experiencing as well as how much pain they have experienced in the past 24 hours. The patient's level of pain might be represented by the average of three evaluations or by any single value

Migraine Specific Quality of Life Questionnaire (MSQ Version 2.1)

Time Frame: From enrollment to the end of treatment at 4 weeks.

This questionnaire is used to evaluate migraine patient's quality of life. The 14-item MSQ version 2.1 measures QOL impacts in three domains: Role function-restrictive (RFR), which measures the functional impact of migraine through limitations on daily social and work activities; Role function-preventive (RFP), which measures the impact of migraine through prevention of daily work and social activities; and Emotional function (EF), which measures the emotional impact of migraine through three items. The raw total score was the sum of all item scores, which were rescaled from 0 to 100, with a higher score denoting better quality of life. Raw scores in each domain were calculated as the sum of all item scores.

Migraine Disability Assessment Scale (MDA)

Time Frame: From enrollment to the end of treatment at 4 weeks.

The Migraine Disability Assessment Scale (MIDAS) is intended to assist individuals and medical professionals in comprehending how migraines affect day-to-day living. MIDAS gives a more accurate view of the overall impact of migraines by evaluating how frequently they occur and how they interfere with social activities, employment, and domestic duties. It is simpler to customize therapy to meet each patient's needs when the information is used to determine treatment choices and monitor progress overtime. In the end, it's a tool that facilitates improved communication and assistance in migraine management by allowing patients to share their experiences and difficulties.

Secondary Outcomes

  • ROM Cervical Spine (Flexion)(From enrollment to the end of treatment at 4 weeks.)
  • ROM Cervical Spine (Extension)(From enrollment to the end of treatment at 4 weeks.)
  • ROM Cervical Spine (Lateral Flexion) Left Side(From enrollment to the end of treatment at 4 weeks.)
  • ROM Cervical Spine (Lateral Flexion) Right Side(From enrollment to the end of treatment at 4 weeks.)
  • ROM Cervical Spine (Rotation) Left Side(From enrollment to the end of treatment at 4 weeks.)
  • ROM Cervical Spine (Rotation) Right Side(From enrollment to the end of treatment at 4 weeks.)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials